Barclays PLC Genprex, Inc. Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $4,975 - $11,102	-4,112 Reduced 42.26%	5,618 $7,000
Q3 2021 Nov 09, 2021	SELL	$2.59 - $3.36 $5,565 - $7,220	-2,149 Reduced 18.09%	9,730 $26,000
Q2 2021 Aug 13, 2021	SELL	$3.11 - $4.87 $41,481 - $64,956	-13,338 Reduced 52.89%	11,879 $40,000
Q1 2021 May 13, 2021	BUY	$3.66 - $7.67 $57,945 - $121,431	15,832 Added 168.69%	25,217 $109,000
Q4 2020 Feb 11, 2021	SELL	$3.03 - $5.51 $19,234 - $34,977	-6,348 Reduced 40.35%	9,385 $39,000
Q3 2020 Nov 12, 2020	SELL	$2.9 - $4.29 $183,285 - $271,136	-63,202 Reduced 80.07%	15,733 $53,000
Q2 2020 Aug 12, 2020	BUY	$1.99 - $3.64 $157,080 - $287,323	78,935 New	78,935 $247,000
Q1 2020 May 13, 2020	SELL	$0.28 - $6.23 $0 - $6	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$0.24 - $0.75 $0 - $0	1 New	1 $0

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.